PMID- 25592155
OWN - NLM
STAT- MEDLINE
DCOM- 20151117
LR  - 20220716
IS  - 1469-4409 (Electronic)
IS  - 0950-2688 (Print)
IS  - 0950-2688 (Linking)
VI  - 143
IP  - 13
DP  - 2015 Oct
TI  - Association of human leukocyte antigen haplotypes with clearance and persistence 
      of hepatitis B virus infection in northeastern China.
PG  - 2805-12
LID - 10.1017/S0950268814003902 [doi]
AB  - This study investigated clinical implications of human leukocyte antigen (HLA) I 
      and II haplotypes, in combination with HBV sub-genotype C2, in hepatitis B virus 
      (HBV) infections in northeastern China. Here, HLA haplotypes of 230 HBV-infected 
      patients were compared to 210 healthy, unrelated Han individuals. Of the 230 
      HBV-infected patients, 54 had acute self-limited hepatitis (ASH) with 
      sub-genotype C2 (ASH-C2), 144 had chronic hepatitis (CH) with sub-genotypes C2 
      and B2 (CH-C2 and CH-B2), and 32 spontaneously recovered without sub-genotype 
      results. All groups underwent HLA typing and haplotype analysis. The results 
      revealed that A*02-DRB1*12 and A*02-B*15-DRB1*09 carriers were susceptible to HBV 
      infection. A*02-B*15-DRB1*09 is probably associated with acute onset and viral 
      clearance and A*02-DRB1*12, with viral persistence. In HBV infections, 
      B*40-DRB1*12 was associated with HBV persistence, whereas B*46-DRB1*09, 
      A*24-DRB1*14, and B*15-DRB1*04 carriers easily recovered from the disease. By 
      contrast, when infected with the HBV-C2 sub-genotype, A*24-DRB1*14, B*15-DRB1*04, 
      A*02-B*15, A*02-DRB1*15, and A*02-B*15-DRB1*09 carriers displayed an acute 
      clinical course before recovery. This study reveals a relationship between HLA 
      haplotypes and HBV pathogenesis, thereby providing potential therapeutic targets 
      to treat HBV infection.
FAU - Wang, H Y
AU  - Wang HY
AD  - Institute of Harbin Haematology and Oncology, Harbin First 
      Hospital,Harbin,People's Republic of China.
FAU - Wang, F
AU  - Wang F
AD  - Institute of Harbin Haematology and Oncology, Harbin First 
      Hospital,Harbin,People's Republic of China.
FAU - Cheng, M
AU  - Cheng M
AD  - Institute of Harbin Haematology and Oncology, Harbin First 
      Hospital,Harbin,People's Republic of China.
FAU - Liu, Y
AU  - Liu Y
AD  - Institute of Harbin Haematology and Oncology, Harbin First 
      Hospital,Harbin,People's Republic of China.
FAU - Zhang, S Y
AU  - Zhang SY
AD  - Research Center of the Second Affiliated Hospital of Harbin Medical 
      University,Harbin,People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150116
PL  - England
TA  - Epidemiol Infect
JT  - Epidemiology and infection
JID - 8703737
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Case-Control Studies
MH  - China/epidemiology
MH  - Female
MH  - Genotype
MH  - HLA Antigens/*genetics/immunology
MH  - Haplotypes
MH  - Hepatitis B, Chronic/epidemiology/*genetics/immunology
MH  - Humans
MH  - Male
PMC - PMC9151067
OTO - NOTNLM
OT  - Haplotype
OT  - hepatitis B virus infection
OT  - human leukocyte antigen
OT  - sub-genotype
EDAT- 2015/01/17 06:00
MHDA- 2015/11/18 06:00
PMCR- 2022/05/30
CRDT- 2015/01/17 06:00
PHST- 2015/01/17 06:00 [entrez]
PHST- 2015/01/17 06:00 [pubmed]
PHST- 2015/11/18 06:00 [medline]
PHST- 2022/05/30 00:00 [pmc-release]
AID - S0950268814003902 [pii]
AID - 00390 [pii]
AID - 10.1017/S0950268814003902 [doi]
PST - ppublish
SO  - Epidemiol Infect. 2015 Oct;143(13):2805-12. doi: 10.1017/S0950268814003902. Epub 
      2015 Jan 16.